For 1QFY2017, Dr Reddy’s Laboratories (DRL) posted a poor set of numbers. It
posted sales of Rs3,235cr V/s Rs3,900cr expected and V/s Rs3,758cr in 1QFY2016,
a yoy de-growth of 14.0%. The company’s sales will continue to be under
pressure owing to the likelihood of all its major markets posting a muted growth.
Lower sales led to a soft EBIT margin of 3.4% V/s 15.6% expected and V/s 20.2%
in 1QFY2016. Other income came in at ~Rs61cr V/s Rs34cr in 1QFY2016. The net
profit for the quarter stood at Rs126cr V/s Rs520cr expected and V/s Rs626cr in
1QFY2016, posting a yoy de-growth of 79.8%. We maintain our Neutral rating
on the stock.
A subdued quarter: DRL posted a poor set of numbers for the quarter. It posted
sales of Rs3,235cr V/s Rs3,900cr expected and V/s Rs3,758cr in 1QFY2016, a yoy
de-growth of 14.0%. The generic business (Rs2,663.8cr) posted a yoy de-growth of
14.0% owing to USA, Europe and Emerging Markets posting a de-growth of 16%,
16% and 26% yoy respectively. The Indian market on the other hand posted a yoy
growth of 10.0% yoy. The PSAI segment (Rs469.2cr) posted a de-growth of 16%
yoy while proprietary products and others posted a flat yoy growth of 1.0% to
Rs101.5cr. Lower sales led to a soft EBIT margin of 3.4% V/s 15.6% expected and
20.2% in 1QFY2016. Other income came in at ~Rs61cr V/s Rs34cr in 1QFY2016.
The net profit for the quarter stood at Rs126cr V/s Rs520cr expected and V/s Rs626cr
in 1QFY2016, posting a yoy de-growth of 79.8%.
Outlook and valuation: We expect net sales to grow at a CAGR of 8.2% to
Rs18,119cr and adjusted EPS to record a 6.9% CAGR to Rs157.8 over
FY2016-18E. We recommend a Neutral rating on the stock given the valuations.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...